Agenus Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Agenda's fourth quarter 2021 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone keypad. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today. Ms. Divya Vasudevan, please go ahead.

Thank you. And thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory, and commercial plans and timelines, including timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks. As another reminder, this call is being recorded for audio broadcast. Joining me today are Dr. Gerald Arman, Chairman and Chief Executive Officer, Dr. Stephen O'Day, Chief Medical Officer, Dr. Jennifer Buell, Chief Executive Officer of Mink Therapeutics, Chandresh Harjeevan, Chief Operating Officer of Saponix, and Christine Klaskin, Vice President of Finance. With that, I'll turn the call over to Gero to highlight the progress that we've made to date this year. Gero?

Thank you, Divya. Thank you all for your participation and your interest in Agenis. As I go through our call today, I'll be referencing slide numbers from time to time on the presentation that appears on your screen. You can also find slides on the events and presentations page of our website. To start with, at last year's shareholder meeting, we tried to streamline our business model. And based on that, our business model is comprised of four pillars. This approach allows us to strategically develop our pipeline independently, as well as with partners, to build value while de-risking development and accelerating our path to market. The first pillar consists of our value creators, our fully or majority-owned programs, such as Fulton Sillimab. That's our next generation CTLA-4. previously known as 1181. We intend to develop and commercialize these programs that fall into this category in certain geographies ourselves and partner in other geographies in order to create upfront value for the company and de-risk development. The second pillar consists of potential cash generators through strategic partnerships. such as what we have done with AGEN 1777, our TIGIT by specific license to BMS. We have received over $800 million in cash through upfront and achieved milestone payments from these types of transactions over the past five, six years and are eligible for additional $2.8 billion in milestones and royalties. as well as the option to participate in development and commercialization of these products. Three, the third pillar consists of enablers, such as our PD-1 antibody, Bostilumab. These backbone therapies are being evaluated in combination with our pipeline and through clinical collaboration with other partners. They provide additional opportunities for commercialization and revenue generation while de-risking development through one centralized entity. Four, the fourth pillar is represented by our subsidiaries, Mink Therapeutics and Saponix. While Agenis retains majority ownership in these entities, They are structured for independent financing, which allows for focus and accelerated development of their respective products. I would like to begin the call by addressing the first pillar, which is driven by our flagship program, Botansilomat. As you know, we have treated well over 100 patients in Phase I trials evaluating botansilumab as monotherapy and in combination with bostilumab. We presented data at the CITSE meeting last year, which demonstrated that botansilumab has an improved efficacy and safety profile compared to what has been reported with previous CTLA-4 antibodies. that is both first-generation and the next generation. As shown on slide three, botansilumab, by the way, you can advance these slides on your own. We don't have the means to do that from here for you. As shown on slide three, botansilumab is FC-enhanced to improve the efficacy and safety of CTLA-4 blockade through three primary mechanisms. First is botansilumab is designed to extend the curative benefits of immuno-oncology to cold tumors that do not typically respond to approved immunotherapies. This is achieved by increasing potency through improved T-cell activation, priming memory formation, and counteracting the immunosuppressive activity of regulatory T cells, all in one antibody. As presented at CITC, Botansilumab is the first CTLA-4 inhibitor to demonstrate clinical responses across nine, nine cold and treatment-resistant cancers. Second, botansilumab is designed to expand clinical benefit in hot tumors, such as melanoma, where CTLA-4 is already approved, but results in clinical benefit in only a third of patients and long-term survival in less than a quarter of the patients. So there is a lot of room to improve here. We have observed responses across both hot and cold cancers in patients. We expressed a biomarker associated with poor outcomes to first-generation CTLA-4. And finally, Botansilumab is designed to improve safety by reducing or eliminating side effects that cause treatment discontinuation. Notably, no pneumonitis, carditis, neurological toxicities have been observed so far. Now, with that, I would like to turn the call over to our Chief Medical Officer, Dr. Stephen O'Day, who is one of the global experts in this field to review our upcoming plans for PotencilaMAP. Steven?